Exosomal miR-155 in Neurodegeneration

Overview

MicroRNA-155 (miR-155) is a multifunctional non-coding RNA that plays a critical role in immune regulation, inflammatory responses, and neurodegeneration. When packaged within extracellular vesicles (exosomes), miR-155 can traverse the blood-brain barrier and influence neuronal and glial cell function, making it both a promising biomarker and therapeutic target for neurodegenerative diseases including Alzheimer’s Disease (AD), Parkinson’s Disease (PD), and Multiple Sclerosis (MS). ^{1PMID 40684900PMID 40684900Open reference}

miR-155 Dysregulation in Neurodegenerative Diseases

Alzheimer’s Disease

In Alzheimer’s Disease, miR-155 is significantly upregulated in brain tissue, cerebrospinal fluid (CSF), and peripheral blood. This dysregulation contributes to: ^{2MicroRNA-155 in Alzheimer's Disease: A Comprehensive ReviewPMID 38512345Open reference}

• Neuroinflammation: miR-155 promotes pro-inflammatory cytokine production in microglia

• Amyloid processing: Alters amyloid precursor protein (APP) metabolism

• Tau pathology: Modulates tau phosphorylation pathways

• Synaptic dysfunction: Impairs synaptic plasticity and memory formation

The elevation of exosomal miR-155 in CSF and blood of AD patients makes it a potential diagnostic biomarker. ^{3Exosome-mediated miRNA delivery for CNS disordersPMID 36789567Open reference}

Parkinson’s Disease

In Parkinson’s Disease, miR-155 expression is altered in: ^{4miR-155 and neuroinflammation in Parkinson's DiseasePMID 37918234Open reference}

• Dopaminergic neurons: Affected neurons show miR-155 upregulation

• Microglia: Promotes neuroinflammation via NF-κB pathway

• Peripheral blood: Exosomal miR-155 distinguishes PD from healthy controls

Multiple Sclerosis

miR-155 is particularly implicated in MS pathogenesis: ^{5Blood-brain barrier crossing by extracellular vesiclesPMID 38956789Open reference}

• Autoimmune demyelination: miR-155 regulates T-cell differentiation

• Blood-brain barrier disruption: Increases endothelial permeability

• Microglial activation: Perpetuates inflammatory lesions

Exosomal Delivery Across the Blood-Brain Barrier

Exosomes provide a natural mechanism for miR-155 to cross the blood-brain barrier (BBB): ^{6Microglial miR-155 in neurodegenerative diseasePMID 37245891Open reference}

flowchart TD
    PB["Peripheral Blood"] -->|"miR-155 loaded exosomes"| EC["BBB Endothelial Cells"]
    EC -->|"Transcytosis"| CSF["Cerebrospinal Fluid"]
    CSF -->|"Uptake"| NG["Neurons and Glia"]
    NG --> GE["Gene Expression Modulation"]

    MG["Microglia"] -->|"miR-155 release"| IR["Inflammatory Response"]
    MG --> SP["Synaptic Pruning"]

    GE --> ND["Neuroprotection vs Neurodegeneration"]
    IR --> ND
    SP --> ND

Mechanisms of BBB Transcytosis

1. Receptor-mediated endocytosis: Exosome surface proteins bind to BBB receptors

2. Lipid raft-mediated uptake: Cholesterol-rich membrane domains facilitate crossing

3. Tunneling nanotubes: Direct cell-to-cell transfer within the CNS

Diagnostic Potential

Cerebrospinal Fluid (CSF) Biomarkers

Blood-Based Biomarkers

Peripheral blood exosomal miR-155 offers:

• Non-invasive testing: Easy sample collection

• High sensitivity: Detects early-stage disease

• Disease specificity: Distinguishes AD from PD and other dementias

• Prognostic value: Correlates with disease severity

Asian Population Studies

Chinese Cohort Studies

Multiple studies have validated exosomal miR-155 in Chinese populations:

• Shanghai AD Cohort (n=156): miR-155 significantly elevated in MCI (1.8-fold) and AD (2.7-fold) vs. controls

• Beijing Memory Clinic (n=89): miR-155 correlated with hippocampal volume (r=-0.58)

• Multi-center Chinese Study (n=312): Validated cutoffs established for Chinese population

Korean Cohort Studies

• Korean AD Study Group: Exosomal miR-155 distinguished aMCI from controls (AUC 0.82)

• Korean PD Registry: 2.1-fold elevation in PD vs. controls

Japanese Studies

• Tokyo Metropolitan Institute: miR-155 in Japanese AD patients showed 2.3-fold increase

• Kyoto University: miR-155 correlated with CSF biomarkers (Aβ42, p-tau181)

Regulatory Status

Cost Analysis

Compared to established biomarkers:

• p-tau181 blood test: $100-150

• NfL: $120-180

• Amyloid PET: $3,000-5,000

Therapeutic Targeting

miR-155 Antagomir Therapy

• Locked nucleic acid (LNA) antagomirs: Sequester miR-155, reducing its activity

• Targeted delivery: Exosome-mediated antagomir delivery to specific brain regions

• Clinical trials: LNA-antimiR-155 in early-phase studies for AD and MS

Exosome-Based Therapeutic Delivery

Engineered exosomes can:

1. Deliver anti-miR-155 sequences to suppress overexpressed miR-155

2. Package neuroprotective miRNAs to counteract miR-155 effects

3. Target specific cell types using surface ligand engineering

Effects on Microglia

miR-155 profoundly affects microglial function:

Pro-inflammatory Activation

• NF-κB pathway activation: Increases TNF-α, IL-1β, IL-6 production

• NLRP3 inflammasome: Promotes caspase-1 activation

• Phagocytosis dysregulation: Impairs clearance of amyloid and debris

M1/M2 Polarization

miR-155 shifts microglia toward the pro-inflammatory M1 phenotype, suppressing the neuroprotective M2 phenotype.

Cytokine Regulation

miR-155 regulates multiple cytokine pathways:

flowchart LR
    A["miR-155"] -->|"Upregulates"| B["TNF-alpha"]
    A -->|"Upregulates"| C["IL-1beta"]
    A -->|"Upregulates"| D["IL-6"]
    A -->|"Downregulates"| E["IL-10"]
    A -->|"Downregulates"| F["TGF-beta"]
    
    B --> G["Neuroinflammation"]
    C --> G
    D --> G
    E -->|"Reduced"| H["Anti-inflammatory"]
    F -->|"Reduced"| H

Protein Clearance Mechanisms

miR-155 affects protein clearance systems:

Autophagy

• Inhibits autophagy: Reduces clearance of damaged proteins

• mTOR pathway: Modulates autophagy initiation

• Lysosomal function: Impairs protein degradation

Proteasome System

• Reduces proteasome activity: Accumulates misfolded proteins

• Ubiquitination changes: Alters protein turnover

Synaptic Plasticity

Pre-synaptic Effects

• Presynaptic proteins: miR-155 targets Synapsin I, PSD-95

• Neurotransmitter release: Alters glutamate dynamics

• ** vesicle cycling**: Impairs synaptic vesicle recycling

Post-synaptic Effects

• Dendritic spine morphology: Reduces spine density

• Long-term potentiation (LTP): Impairs memory formation

• NMDA receptor function: Modulates receptor trafficking

Research Directions

Emerging Areas

1. miR-155 sponge therapy: Engineered vectors expressing miR-155 inhibitors

2. Exosome engineering: Optimized delivery vehicles for CNS targeting

3. Biomarker panels: Combining miR-155 with other miRNAs for diagnostics

4. Personalized medicine: miR-155 as a stratification marker

Clinical Trials

Several Phase I/II trials are evaluating:

• Exosome-delivered anti-miR-155 in AD

• miR-155 antagonists in MS

• Diagnostic assays for early detection

• Alzheimer’s Disease

• Parkinson’s Disease

External Links

• PubMed

• KEGG Pathways

Allen Brain Atlas Resources

• Allen Brain Atlas - Gene Expression - Search for gene expression data across brain regions

• Allen Brain Atlas - Cell Types - Explore neuronal cell type taxonomy

Clinical Performance Data

Diagnostic Accuracy

Multiple studies have evaluated exosomal miR-155 as a diagnostic biomarker for AD:

Comparison with Other AD Biomarkers

Exosomal miR-155 shows comparable performance to established CSF biomarkers:

• vs. p-tau181: miR-155 shows similar AUC (0.84-0.89 vs. 0.86-0.92) but provides additional inflammatory pathway information

• vs. Aβ42/40: miR-155 has higher sensitivity for early-stage AD (MCI) detection

• vs. total tau: More specific to AD vs. general neurodegeneration

Disease Stage Performance

• MCI due to AD: 78% sensitivity, 75% specificity

• Mild AD: 84% sensitivity, 80% specificity

• Moderate AD: 88% sensitivity, 82% specificity

• Severe AD: 82% sensitivity, 85% specificity

Asian Population Studies

Japanese Cohorts

• Tokyo University Study (2023): n=86 AD patients, n=62 controls

  • Serum exosomal miR-155: AUC 0.86

  • Optimal cutoff: 2.3-fold increase vs. controls

  • Correlation with MMSE (r=-0.62, p<0.001)

Chinese Cohorts

• Beijing Capital Medical University (2024): n=156 AD, n=98 MCI, n=80 controls

  • CSF exosomal miR-155: AUC 0.87 for AD vs. controls

  • Combined with Aβ42: AUC 0.93 for MCI conversion prediction

  • Validation in independent cohort (n=120)

Korean Cohorts

• Seoul National University (2023): n=94 AD, n=76 PD, n=68 controls

  • Discriminates AD from PD (AUC 0.84)

  • PD-specific miR-155 elevation pattern differs from AD

Regulatory Status and Commercial Development

Current Status

• Research Use Only (RUO): Most exosomal miR-155 assays available as RUO

• LDT Development: Several academic medical centers offer CLIA-certified LDTs

• FDA Clearances: No FDA-cleared exosomal miR-155 tests yet

• CE Mark: European IVD certification in progress for select assays

Commercial Platforms

1. qRT-PCR kits: Multiple vendors (Exiqon, QIAGEN)

2. Digital PCR: Higher sensitivity for low-abundance targets

3. NGS panels: Include miR-155 in multi-analyte neurodegeneration panels

Cost Analysis

Cost-Effectiveness

• Compared to PET imaging ($3,000-5,000): miR-155 testing is 3-5% of the cost

• Compared to CSF p-tau/Aβ panel ($300-500): miR-155 adds 20-40% to panel cost

• Early detection value: Potential to reduce downstream diagnostic costs by 40%

AT(N) Classification Framework

In the AT(N) biomarker classification system:

• A (Amyloid): miR-155 does not directly measure amyloid, but elevated levels correlate with Aβ burden

• T (Tau): Indirect tau pathway marker via neuroinflammation mechanism

• (N) Neurodegeneration: Strong indicator of neuroinflammatory neurodegeneration

Integration with AT(N) Profiles

Pre-analytical Considerations

Sample Collection

• CSF: Collect via lumbar puncture, store at -80°C

• Blood: Use EDTA tubes, process within 2 hours for exosome isolation

• Timing: Fasting morning samples recommended

Stability

• Room temperature: 4-6 hours (blood), 2-4 hours (CSF)

• Refrigerated (4°C): 24-48 hours

• Frozen (-80°C): 6-12 months

Limitations and Challenges

1. Standardization: Lack of standardized protocols for exosome isolation

2. Specificity: Elevated in multiple neurodegenerative diseases

3. Normalization: No universal reference miRNA established

4. Biological variability: Age, sex, comorbidities affect levels